Biopharma's Brass Hid Anxiety Drug Trial Risks, Investor Says
Vistagen Therapeutics' current and former top brass have been hit with a derivative shareholder suit in California federal court alleging they overstated its clinical trial for a novel, anti-anxiety drug while...To view the full article, register now.
Already a subscriber? Click here to view full article